Previous 10 | Next 10 |
SELLAS Life Sciences Announces Positive Readout for Leukemia Drug SELLAS Life Sciences' ( SLS ) stock shot up as the company reported positive results from its Phase 1/2 study of its Galinpepimut-S treatment for patients with acute myeloid leukemia. The trial demonstrated that the patients...
Overview Cara Therapeutics focuses on developing therapies to treat itching, called pruritus, which is an unfortunate side effect for a lot of diseases. Cara’s late stage candidate, CR845 (Korsuva), initially targeted post-op pain. The company made the switch from focusing on pain...
SmileDirectClub (NASDAQ: SDC ) -24% on Q4 earnings . More news on: SmileDirectClub, Inc., Spherix Incorporated, Fossil Group, Inc., Stocks on the move, , Read more ...
Menlo Therapeutics (NASDAQ: MNLO ) -21.3% pre-market after saying a Phase 2 clinical trial failed to meet its primary endpoint to show a statistically significant reduction in chronic pruritus of unknown origin in patients treated with once daily oral serlopitant. More news on: Menlo T...
REDWOOD CITY, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, today announced results from its Phase 2 clinical trial evaluating the safety and efficacy of once daily oral serlopitant for the treatment of chronic prur...
REDWOOD CITY, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, today announced it will host a conference call and webcast on Wednesday, February 26, 2020 at 8:30 am ET (5:30 am PT) to discuss results from the Phase 2 t...
REHOVOT, Israel, BRIDGEWATER, N.J. and REDWOOD CITY, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) and Menlo Therapeutics Inc. (Nasdaq: MNLO) today announced that the shareholders of Foamix and stockholders of Menlo voted to approve all shareholder and...
REDWOOD CITY, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced the publication of the company’s Phase 2 trial of ser...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Foamix ( FOMX ) is an Israeli biotech company that has a number of dermatological products in various stages of clinical trials and one already FDA-approved and about to launch (January 2020). It is merging with Menlo ( MNLO ), which has another interesting product currently in Phase II clin...
News, Short Squeeze, Breakout and More Instantly...
BRIDGEWATER, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the upcoming H.C. Wainwright 22 nd Annual Global Investment Confe...
BRIDGEWATER, N.J. , Sept. 8, 2020 /PRNewswire/ -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today completed its previously announced corporate name change from Menlo Therapeutics Inc. to VYNE Therapeutics Inc. and the change of its ticker symbol from "MNLO" to "...
Company will commence trading under new ticker “VYNE” on September 8, 2020 Company to ring Nasdaq Closing Bell on September 8 BRIDGEWATER, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”...